Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.68 |
| ▸ | ACHE | P22303 | 3/20 | 0.67 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798221 | 0.89 | ACHE (0.64) | TRPV1ACHEABCG2TRPM8MAPT | |
| SCHEMBL798212 | 0.88 | MEN1 (0.65) | TRPV1ACHEABCG2KMT2APOLB | |
| SCHEMBL12503790 | 0.87 | ABCG2 (0.71) | TRPV1ACHEABCG2KMT2APOLB | |
| SCHEMBL6919747 | 0.85 | TRPV1 (0.88) | TRPV1ACHEKMT2APOLBMEN1 | |
| SCHEMBL8802625 | 0.81 | FAAH (0.76) | TRPV1ACHEKMT2APOLBTRPM8 | |
| SCHEMBL9936354 | 0.81 | TRPV1 (1.00) | TRPV1ACHEKMT2APOLBMEN1 | |
| SCHEMBL7501961 | 0.79 | KMT2A (0.81) | TRPV1ACHEKMT2APOLBMEN1 | |
| SCHEMBL6923780 | 0.79 | MTNR1A (0.82) | KMT2APOLBTRPM8MEN1MAPT | |
| SCHEMBL798092 | 0.79 | KMT2A (0.80) | TRPV1KMT2APOLBMEN1MTNR1A | |
| SCHEMBL7023429 | 0.79 | TRPV1 (0.77) | TRPV1ACHEKMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901317-B2 | Tryptamine derivatives, their preparation and their use in gastropathy | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-02 | — | — | US | disclosed |
| US-20130197052-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | UNIVERSITY OF CALCUTTA (IN) | 2013-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197052-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | HTRA2, AIFM1, SI | TRPV1 253/4885ACHE 1333/4885ABCG2 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.